Sign in to view content

ZETA-1 Phase 2 Trial Safety and Tolerability Results for APX3330 a New Oral Ref-1 Inhibitor for the Treatment of Diabetic Retinopathy

Daniel Su, MD

Video
Published 2023

Related

Impact of PRAME Status on Gene Expression Profile to Predict Metastasis in Uveal Melanoma: Interim Analysis of the Collaborative Ocular Oncology Group Study Number 2 (COOG2)
Prithvi Mruthyunjaya, MD, MHS
Updates from the Field
2022
Acute Retinal Periphlebitis and Panuveitis OD
Deepayan Kar
Retina Image Bank: Images of the Week
2014
Staring a Clinical Trials Program
David A. Eichenbaum, MD, FASRS
Updates from the Field
2019

Category: Diabetic Retinopathy

See more